TABLE 5

Hospital encounters where treatment regimen was prescribed by comorbidity for laboratory-confirmed Mycobacterium avium complex cases, among encounters where treatment was received

Pulmonary NTMAlveolitis/pneumonitisBronchiectasisCoccidioidomycosisCOPDCFHistoplasmosisIPFNeoplasmNon-HIV immunodeficiencySarcoidosisTB
Subjects189211214209324415978
Macrolide, ethambutol, rifamycin (optional aminoglycoside)#72 (38)0 (0)21 (19)0 (0)88 (21)3 (33)1 (33)0 (0)7 (16)5 (33)2 (22)35 (45)
Macrolide monotherapy16 (8)1 (50)22 (20)0 (0)66 (16)0 (0)0 (0)0 (0)12 (27)3 (20)0 (0)0 (0)
Macrolide, quinolone14 (7)0 (0)12 (11)0 (0)38 (9)1 (11)0 (0)0 (0)4 (9)0 (0)2 (22)1 (1)
Macrolide, rifamycin6 (3)1 (50)3 (3)0 (0)6 (1)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)1 (1)
Macrolide, amikacin+0 (0)0 (0)0 (0)0 (0)1 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)
Macrolide, linezolid+1 (1)0 (0)0 (0)0 (0)7 (2)0 (0)0 (0)0 (0)1 (2)0 (0)0 (0)0 (0)
Macrolide, other+28 (15)0 (0)8 (7)0 (0)37 (9)1 (11)0 (0)0 (0)2 (5)0 (0)1 (11)14 (18)
Ethambutol, rifamycin§4 (2)0 (0)1 (1)0 (0)11 (3)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)9 (12)
Quinolone-based§42 (22)0 (0)43 (38)1 (100)159 (38)2 (22)1 (33)2 (100)16 (36)5 (33)4 (44)1 (33)
Aminoglycoside-based§3 (2)0 (0)0 (0)0 (0)1 (0)2 (22)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)
Linezolid-based§3 (2)0 (0)2 (2)0 (0)6 (1)0 (0)1 (33)0 (0)2 (5)2 (13)0 (0)0 (0)

Data are presented as n or n (%). NTM: nontuberculous mycobacteria; COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; IPF: idiopathic pulmonary fibrosis; TB: tuberculosis. #: treatment regimens meeting American Thoracic Society/Infectious Disease Society of America guidelines; : treatment regimens that potentially promote macrolide resistance; +: treatment regiments that are of unknown clinical significance; §: treatment regimens that do not include macrolides.